In November 2013, work on ibuprofen was recognized by the erection of a Royal Society of Chemistry blue plaque at Boots Beeston Factory site in Nottingham, which reads:
In recognition of the work during the 1980s by The Boots Company PLC on the development of ibuprofen which resulted in its move from prescription only status to over the counter sale, therefore expanding its use to millions of people worldwide
and another at BioCity Nottingham, the site of the original laboratory, which reads:
In recognition of the pioneering research work, here on Pennyfoot Street, by Dr Stewart Adams and Dr John Nicholson in the Research Department of Boots which led to the discovery of ibuprofen used by millions worldwide for the relief of pain. Society and culture
Availability
Ibuprofen was made available under prescription in the United Kingdom in 1969, and in the United States in 1974. In the years since, the good tolerability profile, along with extensive experience in the population, as well as in so-called phase-IV trials (postapproval studies), have resulted in the availability of ibuprofen OTC in pharmacies worldwide, as well as in supermarkets and other general retailers. Ibuprofen is its International nonproprietary name (INN), British Approved Name (BAN), Australian Approved Name (AAN) and United States Adopted Name (USAN). In the U.S., Motrin has been on the market since 1974, and Advil has been on the market since 1984.
Cardiovascular risk
Along with several other NSAIDs, chronic ibuprofen use has been found correlated with risk of progression to hypertension in women, though less than for acetaminophen, and myocardial infarction (heart attack), particularly among those chronically using higher doses. On 9 July 2015, the U.S. Food and Drug Administration (FDA) toughened warnings of increased heart attack and stroke risk associated with ibuprofen and related NSAIDs; the NSAID aspirin is not included in this warning. The European Medicines Agency (EMA) issued similar warnings in 2015. Skin
Along with other NSAIDs, ibuprofen has been associated with the onset of bullous pemphigoid or pemphigoid-like blistering. As with other NSAIDs, ibuprofen has been reported to be a photosensitising agent, but it is considered a weak photosensitising agent compared to other members of the 2-arylpropionic acid class. Like other NSAIDs, ibuprofen is an extremely rare cause of the autoimmune disease Stevens–Johnson syndrome (SJS). Ibuprofen is also an extremely rare cause of toxic epidermal necrolysis. Interactions
Alcohol
Drinking alcohol when taking ibuprofen may increase the risk of stomach bleeding. Aspirin
According to the Food and Drug Administration (FDA), "ibuprofen can interfere with the antiplatelet effect of low-dose aspirin, potentially rendering aspirin less effective when used for cardioprotection and stroke prevention". Allowing sufficient time between doses of ibuprofen and immediate-release (IR) aspirin can avoid this problem. The recommended elapsed time between a dose of ibuprofen and a dose of aspirin depends on which is taken first.